Cargando…

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer

Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Koltai, Tomas, Cardone, Rosa A., Reshkin, Stephan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862380/
https://www.ncbi.nlm.nih.gov/pubmed/31683667
http://dx.doi.org/10.3390/ijms20215438
_version_ 1783471540557316096
author Koltai, Tomas
Cardone, Rosa A.
Reshkin, Stephan J.
author_facet Koltai, Tomas
Cardone, Rosa A.
Reshkin, Stephan J.
author_sort Koltai, Tomas
collection PubMed
description Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment in very advanced human cancer. However, one of the main limitations of this therapy is its short-term effectiveness: 6 to 12 months, after which resistance develops. pH-centered cancer treatment (pHT) has been proposed as a complementary therapy in cancer, but it has not been adopted or tested as a mainstream protocol, in spite of existing evidence of its advantages and benefits. Many of the factors directly or indirectly involved in MC and anti-angiogenic treatment resistance are appropriately antagonized by pHT. This led to the testing of an association between these two treatments. Preliminary evidence indicates that the association of MC and pHT has the ability to reduce anti-angiogenic treatment limitations and develop synergistic anti-cancer effects. This review will describe each of these treatments and will analyze the fundamentals of their synergy.
format Online
Article
Text
id pubmed-6862380
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68623802019-12-05 Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer Koltai, Tomas Cardone, Rosa A. Reshkin, Stephan J. Int J Mol Sci Review Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment in very advanced human cancer. However, one of the main limitations of this therapy is its short-term effectiveness: 6 to 12 months, after which resistance develops. pH-centered cancer treatment (pHT) has been proposed as a complementary therapy in cancer, but it has not been adopted or tested as a mainstream protocol, in spite of existing evidence of its advantages and benefits. Many of the factors directly or indirectly involved in MC and anti-angiogenic treatment resistance are appropriately antagonized by pHT. This led to the testing of an association between these two treatments. Preliminary evidence indicates that the association of MC and pHT has the ability to reduce anti-angiogenic treatment limitations and develop synergistic anti-cancer effects. This review will describe each of these treatments and will analyze the fundamentals of their synergy. MDPI 2019-10-31 /pmc/articles/PMC6862380/ /pubmed/31683667 http://dx.doi.org/10.3390/ijms20215438 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Koltai, Tomas
Cardone, Rosa A.
Reshkin, Stephan J.
Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
title Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
title_full Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
title_fullStr Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
title_full_unstemmed Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
title_short Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
title_sort synergy between low dose metronomic chemotherapy and the ph-centered approach against cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862380/
https://www.ncbi.nlm.nih.gov/pubmed/31683667
http://dx.doi.org/10.3390/ijms20215438
work_keys_str_mv AT koltaitomas synergybetweenlowdosemetronomicchemotherapyandthephcenteredapproachagainstcancer
AT cardonerosaa synergybetweenlowdosemetronomicchemotherapyandthephcenteredapproachagainstcancer
AT reshkinstephanj synergybetweenlowdosemetronomicchemotherapyandthephcenteredapproachagainstcancer